Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
评估吉卡替尼与羟基脲在中危-2或高危骨髓纤维化患者中的疗效:一项随机3期研究的最终分析结果
期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-024-01202-8
Zhang, Yi; Zhou, Hu; Suo, Shanshan; Zhuang, Junling; Yang, Linhua; He, Aili; Liu, Qingchi; Du, Xin; Gao, Sujun; Li, Yarong; Li, Yan; Chen, Yuqing; Wu, Wen; Zhu, Huanling; He, Guangsheng; Hong, Mei; Jiang, Qian; Jiang, Zhongxing; Jing, Hongmei; Wang, Jishi; Xu, Na; Yue, Lingling; Zheng, Cuiping; Zhou, Zeping; Jin, Chenghao; Li, Xin; Liu, Lin; Xu, Yajing; Wu, Dengshu; Zhang, Feng; Zhang, Jin; Wu, Liqing; Yin, Hewen; Lv, Binhua; Xiao, Zhijian; Jin, Jie